\
&
Contact us
\
&
Contact us
This was 4 years ago
Locationvirtual
ProgrammesThe Estonian Research Council (ETAg) organises a webinar on the open access publishing requirements in Horizon Europe. The webinar consists of two parts: the first hour will be held in English and the second part in Estonian. The speaker in the first hour is Ms. Victoria Tsoukala (Policy Officer on Open Access and European Open Science Cloud) from the European Commission. Topics that will be covered are the research publishing requirements in Horizon Europe as well as an introduction to the new open access publishing platform Open Research Europe (ORE). The seond half will provide an insight to the subject matter specifically in the Estonian context.
Researchers and research administrators whom inted to apply for Horizon Europe are welcome to take part in this free webinar. Please register beforehand via https://etag.clickmeeting.com/avatud-juurdepaas-euroopa-horisont-ja-eesti-kontekst-open-access-in-horizon-europe/register
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
